Absci Corporation (ABSI)
$
2.69
+0.10 (3.72%)
Key metrics
Financial statements
Free cash flow per share
-0.6171
Market cap
343.1 Million
Price to sales ratio
94.3712
Debt to equity
0.0414
Current ratio
5.7175
Income quality
0.7106
Average inventory
0
ROE
-0.5369
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Absci Corporation, a drug and target discovery company founded in 2011 and headquartered in Vancouver, Washington, provides biologic drug candidates and production cell lines for partners in the United States using its integrated drug creation platform. This platform unifies the processes of drug discovery and cell line development, allowing for the efficient creation of biologics. The company recorded an operating income of -$108,888,000.00 reflecting its earnings from core operations. Furthermore, with a weighted average number of diluted shares outstanding at 110,239,870.00 the company illustrates potential dilution effects. Absci reported an income before tax of -$103,036,000.00 showcasing its pre-tax profitability while earning an interest income of $0.00 highlighting the effectiveness of its financial investments. The company achieved a revenue of $4,534,000.00 indicating its niche market focus and commitment to advancing drug development. In the financial landscape, Absci’s stock is affordable at $2.59 making it suitable for budget-conscious investors. The stock has a high average trading volume of 3,193,908.00 indicating strong liquidity, which can attract a diverse range of investors. With a market capitalization of $343,133,710.00 the company is classified as a small-cap player, positioning it as a dynamic entity within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with innovative solutions. Additionally, Absci belongs to the Healthcare sector, driving innovation and growth, and emphasizing its pivotal role in shaping the future of drug discovery and development.
Is Absci Corporation (ABSI) a good investment?
Investing in Absci Corporation (ABSI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Absci Corporation (ABSI)'s stock forecast?
Analysts predict Absci Corporation stock to fluctuate between $2.01 (low) and $6.33 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Absci Corporation's market capitalization?
As of 2025-07-03, Absci Corporation's market cap is $343,133,710, based on 127,559,000 outstanding shares.
How does Absci Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Absci Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Absci Corporation (ABSI) stock?
To buy Absci Corporation (ABSI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABSI. Place an order (Market, Limit, etc.).
What is the best time to invest in Absci Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Absci Corporation perform in the last earnings report?
Revenue: $4,534,000 | EPS: -$0.94 | Growth: -21.67%.
Where can I find Absci Corporation's investor relations reports?
Visit https://www.absci.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Absci Corporation?
You can explore historical data from here
What is the all-time high and low for Absci Corporation stock?
All-time high: $31.53 (2021-08-04) | All-time low: $1.11 (2023-10-26).
What are the key trends affecting Absci Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Brendan Smith - TD Cowen Gil Blum - Needham & Company George Farmer - Scotiabank Debanjana Chatterjee - Jones Li Chen - H.C. Wainwright Operator Thank you for standing by, and welcome to Absci's First Quarter 2025 Business Update and Financial and Operating Results Conference Call.
zacks.com
Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago.
seekingalpha.com
Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offers potential upside but increases burn rates and development risks. Strategic partnerships, like those with AMD and AstraZeneca, validate Absci's platform but have yet to generate significant revenue.
benzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
seekingalpha.com
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and CBO Christian Stegmann - SVP of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Vikram Purohit - Morgan Stanley Gil Blum - Needham & Company Debanjana Chatterjee - Jones Operator Thank you for standing by and welcome to Absci's Fourth Quarter and Full Year 2024 Business Update and Financial Operating Results Conference call. At this time, all participants are in listen-only mode.
benzinga.com
Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential.
globenewswire.com
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
seekingalpha.com
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors.
globenewswire.com
Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
globenewswire.com
$20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software $20 Million Equity Investment from AMD Strengthens Absci's Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
See all news
